Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load Compared To Conventional ASDs, With Equal In Vivo Performance

Through using nanocrystalline formulations of new drugs, and reformulating already-marketed ASD products, this webinar with Martti Kaasalainen, Ph.D., Senior Scientist, demonstrates how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

Nanoform’s patented controlled expansion of supercritical solutions (CESS^®️) technology allows the production of particles as small as 50 nanometers, and of different shape and crystallinity, increasing the dissolution rate and helping to create more patient centric dosage forms.

Dr. Kaasalainen leads Nanoform’s small molecule formulation, method development, and innovation activities. He is an experienced scientist with an extensive background in nanoparticle formulation development and characterization for novel, repurposed, and already-marketed drug substances.